Whats new in jpnd
-
Upload
jpndresearch -
Category
Health & Medicine
-
view
467 -
download
4
description
Transcript of Whats new in jpnd
What’s new in JPND?
Marta GomezJPND Management Board Member
19/02/2014
Joint Programming - a definition
European countries engaging
•voluntarily and on a variable geometry basis to tackle a major societal question
•in the definition, development and implementation of a common strategic research agenda
•based on a common vision on how to address major societal challenges.
We cannot tackle neurodegenerative diseases by acting as single countries
AlbaniaAustriaBelgiumCanadaCroatia
Czech RepublicDenmarkFinlandFrance
GermanyGreece
HungaryIrelandIsraelItaly
LuxembourgNetherlands
NorwayPoland
PortugalRomaniaSlovakiaSlovenia
SpainSweden
SwitzerlandTurkeyUnited
Kingdom
JPND is a global research initiative led by EU countries, with 28 participatingEU member statesAssociated countries Third countries
Increasing coordination of national research programmes to improve impact and effectiveness
JPND brings together….
• Researchers (Basic, Clinical, Healthcare/Social)
• National Funding Bodies
• National Research Strategies and Investments
Current JPND strategy
To increase coordinated investment in ND research
aimed at finding causes of disease, developing cures,
and identifying appropriate ways to care for those
with neurodegenerative diseases
• Immediate JPND goals:
• To add value to national investments through coordinated action
• To encourage the development of national research strategies in ND
• To engage in partnership to reach the full potential of JPND
JPND currently partly supported by FP7-JUMPAHEAD (GA. 260774)
Management Board • 27 countries represented• Members mandated to act• Chair Philippe Amouyel - France
Executive Board• Vice-Chair Adriana Maggi - Italy • Robin Buckle - UK• Mogens Horder - Denmark• Marlies Dorlochter - Germany
Scientific Advisory Board• 18 Members, chosen for scientific
excellence and competence
Organisation
Steering CommitteeExecutive Board + •Enda Connolly - Ireland •Rainer Girgenrath - Germany•Edvard Beem - Netherlands
DEFRAGMENTATION- WHAT JPND IS ALL ABOUT
STRATEGIC RESEARCH AGENDA
ALIGNMENT OF EU COUNTRIESON COMMON RESEARCH GOALS
Scientific• Animal models• Biobanks• Cohorts/registries• Disease pathology
Social• Health care delivery• Home automation• Health economics• Ethics
Medical• Early diagnosis• Prevention• Clinical trialsFocus on
Three Domains
Scope of the initiative
JPND Research Strategy (SRA)
• Agreed by 25 Member States + Assoc. Countries
• Officially Launched Feb 7th 2012
• Thematic priorities for future research:
• The origins of neurodegenerative disease
• Disease mechanisms and models
• Disease definitions and diagnosis
• Developing therapies, preventive strategies and interventions
• Healthcare and social care
How can JPND reach its goals?
•Alignment of research in Member Countries
•Partnership with the European Commission
•Partnership with Industry
•Partnership with other international organisations
•Involvement of Patients and Public
JPND Actions to date
• Common European Strategy
• Phase I SRA Implementation (2012-2014)
• Annual Transnational Calls for Proposals
• Action Groups
• National Plans and Strategies
• Communication + Dissemination
SRA Implementation (2012-2014)
Annual Calls for Proposals
Centres of Excellence in Neurodegeneration (CoEN)
•First call (2011) for € 6M – 8 projects
•Second call (2012-13) for € 8M – 5 “Pathfinder” projects
Year Total fund available
Research Area No. of Projects
2011(pilot)
€16M Optimization of biomarkers + harmonization of their use
4
2012 €18M Risk and Protective Factors 5
2012 €11M Evaluation of Healthcare 6
2013 €12M Cross-Disease Analysis open call
2013 €11M Preventive Strategies open call
Call Statistics
Biomarker call2011
Risk factor call2012
Healthcare2012
Nb of proposals submitted / nb of partners / budget requested
14 / 165 / 30.8 M€ 52 / 307 / 97 M€ 22 / 122 / 29 M€
Nb of proposals accepted / nb of partners / budget allocated
4 / 88 / 13.6 M€ 5 / 41 / 17 M€ 6 / 41 / 9 M€
Success rate 29% 10% 27%
Gender breakdown (partners) 23% 28% 42%
Total no. of proposals submitted = 88Total no. of partners involved = 594Overall success rate = 17%
SRA Implementation (2012-2014)
Action Groups
• To determine transnational research needs and opportunities
• Palliative Care (chair: E. Connolly)
• Animal and Cell Models (chair: A. Maggi)
• Assisted Living Technologies (chair J. Hoogendam)
• Longitudinal Cohort Studies (chair: R. Buckle)
• To promote engagement, commitment and partnerships
• Engagement and partnership with the EC (chair: P.
Amouyel)
• Engagement and Partnership with Industry (chair: A. Maggi)
• User and Public Involvement in ND Research (chair: M. Horder)
• Linkage + Alignment of National Plans and Initiatives (chair: E. Hirsch)
Action Group Recommendations
JPND-supported projects
Fact Sheets Publications
Monitoring & Evaluation
• JPND monitoring and evaluation framework
• Questionnaire on ‘attitudes towards JPND’
• External review of strategic direction + implementation
Stakeholder Engagement
Online Partnering Tool
Online Partnering Tool
Create Personal Profile Register Research Group
Online Partnering Tool
Register a proposal idea and form consortia online
Partnering Tool Pilot Phase
480User Profiles
550 User Profiles
(30 Countries)
550 User Profiles
(30 Countries)
Developing and Aligning ND research strategies
•Most JPND countries • No national roadmap • No identified priority actions in the field of ND research
•Those who do, take different approaches • Specific research programmes• National plans targeted to an individual disease (e.g. Dementia) • National plans comprising research, service delivery, both
•Since deciding to participate in JPND, an increasing number of countries are working towards developing SRAs
•Specific JPND actions aimed at encouraging countries to develop national research strategies in ND
Emerging national JPND-related activities
• The Netherlands• Research a major theme as part of National Deltaplan for Dementia
“…. the Deltaplan will follow closely the JPND strategic research agenda and will strengthen the international position of the Netherlands for both research and industry” Edith Schippers, Minister for Health, Welfare and Sport
• United Kingdom• David Cameron’s “Prime Minister’s challenge on dementia” includes
specific references to continued support for COEN and JPND research
• Ireland• National SRA developed to inform participation in JPND• Researchers using participation in 2011 JPND Biomarkers call to start
a national network in biomarkers for Alzheimer’s and Parkinson’s
Partnership with the European Commission
• First call of Horizon 2020 (Dec. 2013)• ERA-NET:
• “Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020”.
• Proposal should:
• coordinate national and regional programmes for research in the area of ND diseases research by implementing a transnational call with EU co-funding
• promote the strategic alignment of research activities
• demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness
• plan the development of key indicators for supporting this.
• implement other joint activities including training and additional joint calls without EU co-funding.
Declaration from G8 summit on dementia
• In response, the OECD is launching a project in 2014 for research on Alzheimer’s and dementia:
• Aimed at strengthening international collaboration and promote data sharing at the international level.
• JPND invited to join the project Advisory Group
• OECD plans a G8 mapping based upon JPND mapping methodology
Keep up to date
• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu
• Sign up to the JPND News Feeds
• Follow JPND Progress pages
• E-mail us: [email protected]
• Follow us on Twitter:
@JPNDEurope